S-1/A: FCHS Pivots to Primary Care, Seeks $19M Public Offering

First Choice Healthcare Solutions, Inc. is undergoing a strategic pivot from its legacy orthopedic business to a national chain of primary care and wellness clinics, supported by a public offering of Series D Convertible Preferred Stock and warrants aiming to raise $19 million.

Summary

• First Choice Healthcare Solutions, Inc. (FCHS) is shifting its business strategy from orthopedic services to developing a national chain of primary care and wellness clinics, focusing on life improvement services (anti-aging, weight management, hormone replacement) and pharmacy services.
• The company plans to terminate all remaining legacy orthopedic and physical therapy services to concentrate resources on the new primary care and wellness clinic model.
• FCHS is acquiring Pointe Medical Services, Inc. (primary care clinic, pharmacy) for $15.8 million, payable in cash, debt assumption/payoff, stock, earn-out, and performance bonus.
• FCHS is also acquiring the physical and intangible assets of The Good Clinic, Inc. (primary care clinic concept) for $3.5 million in an all-stock deal.
• The new corporate structure will include centralized management (Leading Primary Care, Inc. after name change) with three operating subsidiaries: Live Well Medical Group, The Good Clinic Properties, Inc., and Live Well Drugstore, Inc. (compounding pharmacy).
• The public offering aims to raise $19,000,000 in gross proceeds ($17,080,000 net proceeds before expenses, or $19,702,000 if over-allotment option is fully exercised) through the sale of 3,800,000 shares of Series D Convertible Preferred Stock and accompanying warrants.
• The Series D Convertible Preferred Stock will be convertible at an assumed initial conversion price of $5 per share, with warrants exercisable at $5 per share, and will pay cumulative dividends at 9% per annum.
• A 1-for-2,000 reverse stock split of common stock will be effected immediately after the registration statement's effectiveness but prior to NYSE listing, which will not apply to shares issued in the IPO, resale shares, or shares related to the acquisitions of Pointe Med/LiveWell and The Good Clinic.
• The company intends to apply for listing its common stock on the NYSE under the symbol FCHS (or the new name's symbol), with the offering contingent on NYSE approval and raising at least $15.0 million.
• FCHS reported net losses of approximately $3.5 million and $3.9 million for the nine months ended September 30, 2025 and 2024, respectively, with accumulated deficits of $71.3 million and $67.8 million.
• Pointe Med/LiveWell, the acquired entity, reported net income attributable to shareholders of $1,444,050 and $605,682 for the nine months ended September 30, 2025 and 2024, respectively, showing increased sales volume and improved pricing in pharmacy units.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the strategic pivot into high-growth healthcare segments and the acquisitions of profitable entities are positive, the company's significant historical losses, accumulated deficit, and reliance on external capital for its going concern status present substantial risks. The potential for dilution and the speculative nature of the new business model warrant a conservative outlook despite the promising market trends.

Positives

• The strategic pivot to primary care and wellness clinics, combined with compounding pharmacy services, targets high-growth healthcare markets.
• The use of Nurse Practitioners as primary healthcare professionals is expected to provide an approximate 25% labor cost advantage over traditional physician-staffed primary care offices.
• The acquired compounding pharmacy (LiveWell Drugstore) has existing capacity and active licenses in Florida, Georgia, and Mississippi, with plans for expansion and 503B accreditation.
• Pointe Med/LiveWell, the acquired entity, demonstrated positive net income and cash flow from operations, with revenue increasing by 19% for the nine months ended September 30, 2025, compared to the prior year.
• The company's EMR system is cloud-based and complies with Meaningful Use standards, aiming to improve care coordination and reduce hazards from disparate healthcare information systems.
• Centralized administrative infrastructure is designed to achieve economies of scale, reduce expenses, and fuel income growth as the network of clinics expands.
• The company plans to offer a diversified product line including insurance-paid primary care and higher-margin self-pay quality-of-life services, along with pharmacy care and in-clinic product sales.
• The U.S. primary care market is valued at $271.0 billion in 2023 and is projected to grow at a CAGR of 3.36% from 2024 to 2030, indicating a significant market opportunity.

Negatives

• FCHS has a history of minimal profit and recurring net losses, with an accumulated deficit of approximately $71.3 million as of September 30, 2025.
• The company experienced cash outflows from operations of approximately $0.55 million and $0.68 million for the nine months ended September 30, 2025 and 2024, respectively.
• FCHS's ability to continue as a going concern is dependent on raising additional capital and achieving profitability, which is not assured.
• The company's former CEO pled guilty to conspiracy to commit securities fraud, which tarnished the company's reputation and led to a precipitous decline in goodwill and business.
• The company has significant indebtedness, amounting to $24,743,366 as of December 31, 2024, which could restrict financial flexibility and growth.
• The proposed 1-for-2,000 reverse stock split will significantly reduce the number of outstanding common shares, potentially impacting market perception and liquidity for existing shareholders not covered by anti-dilution provisions.
• The Series D Convertible Preferred Stock and Warrants have anti-dilution provisions that could lead to substantial dilution for existing common stockholders if future securities are issued at a lower price.
• There is no established trading market for the Offered Preferred Stock or the Warrants, and the company does not expect one to develop, limiting liquidity.
• The company has broad discretion in the use of net proceeds from the offering, and there is no assurance these funds will be used effectively or successfully for acquisitions and integration.

Risks

• Our business has posted minimal profit since commencing operations, with recurring net losses and significant accumulated deficit.
• If cash from operations is insufficient, the business, financial condition, and results of operations may be materially adversely affected.
• Additional capital is needed to expand operations; failure to raise it will require curtailment or cessation of operations.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies or assets.
• Opening new clinics in multiple markets makes it difficult to evaluate business prospects and manage growth, increasing investment risk.
• Changes in tax laws and unanticipated tax liabilities could adversely affect the effective income tax rate and ability to achieve profitability.
• Quarterly financial results are expected to fluctuate due to demand for services, client retention, economic conditions, marketing costs, and expansion expenses.
• Volatility in financial markets could have a material adverse effect on the business.
• Potential profit margins may decline due to increasing pressure on margins, leading to significant operating losses if costs are not reduced or revenues grown.
• Indebtedness may have a material adverse effect on business, financial condition, and results of operations.
• Pandemics, epidemics, natural disasters, terrorist activities, political unrest, and other outbreaks could have a material adverse impact on business.
• Business interruptions from public health crises could disrupt clinic operations and adversely impact the business.
• Limited operating history impedes the ability to evaluate potential future performance and strategy, making patient acquisition and brand building challenging.
• Acquisitions involve risks that could adversely affect business and internal controls, including integration difficulties and failure to achieve anticipated benefits.
• Inability to attract and retain qualified medical professionals could negatively affect operations, patient attraction, or new clinic openings.
• Difficulties managing growth could lead to higher operating losses or no growth at all.
• Loss of key executives and failure to attract qualified managers could limit growth and negatively impact operations.
• Subject to medical professional liability risks, which could be costly and negatively impact business and financial results.
• The evolving healthcare regulatory and political framework could adversely affect financial condition and results of operations.
• The highly regulated healthcare industry may lead to government authorities determining non-compliance with applicable laws or regulations.
• The practice of pharmacy is highly regulated on state and federal levels; non-compliance could limit compounding pharmacy revenue growth.
• Compounding pharmacies are dependent on consistent availability and quality of base pharmaceuticals; supply chain disruptions pose significant risks.
• Federal and state laws protecting privacy and security of protected health information may increase costs and limit data use, subjecting the company to penalties.
• Quality of life services based primarily on the self-pay model could lead to fewer patients or discounting, limiting growth and negatively impacting operations.
• Changes in third-party reimbursement rates or methods could reduce demand for services or create downward pricing pressure, harming financial position.
• Subject to federal and state restrictions on advertising that may adversely affect the ability to advertise clinics and services.
• HIPAA compliance is critically important; non-compliance could incur substantial expenses.
• Reliance on information technology means any failure, inadequacy, interruption, or security lapse could harm business effectiveness.
• The market for healthcare services is highly competitive; inability to compete could harm the business.
• Forced price reductions due to competition could decline medical revenues and results of operations.
• A decline in consumer disposable income could adversely affect clinical visits and financial results.
• Reduced disclosure requirements for smaller reporting companies may make common stock less attractive to investors.
• Requirements of being a public company may strain resources and distract management.
• Broad discretion in the use of net proceeds from the offering may not be effective.
• Limited trading market for common stock to date; no assurance of an active market developing.
• Market for common stock may fluctuate significantly due to various factors.
• A significant percentage of common stock is held by a small number of shareholders, influencing votes.
• Issuance of common stock from convertible preferred stock and warrants could cause substantial dilution.
• Resales by selling stockholders may have an adverse effect on the market price of common stock.
• No dividends paid in the past and no immediate plans to pay dividends.
• Quarterly operating results are expected to fluctuate, potentially causing stock price decline.
• Penny stock rules may make buying or selling securities difficult, reducing liquidity.
• Former CEO's criminal charges and guilty plea tarnished the company's reputation and goodwill.
• Charter documents and Delaware law may inhibit a takeover.
• Failure to achieve and maintain internal controls could have a material adverse effect on business and stock price.

Future Outlook

The company's go-forward strategy involves creating a national system of innovative, branded primary care and wellness clinics, leveraging two acquisitions (Pointe Med/LiveWell and The Good Clinic) and existing administrative infrastructure. Operations for the new primary care and wellness clinics are expected to commence by March 1, 2026. The plan includes expanding state licensures for the compounding pharmacy and opening a total of thirty new clinics in the next four years, with initial focus on northeast and southwest Florida and Minnesota, and evaluation of Denver and Phoenix markets. The company anticipates sustaining profit margins through economies of scale in back-office operations and aims to achieve financial performance by combining primary care with specialized quality-of-life services and an internal compounding pharmacy.

Management Comments

• Our go forward strategy will be executed using a corporate structure of centralized management services designated as Leading Primary Care, Inc. (which will be the Companys name after the proposed name change from First Choice Healthcare Solutions, Inc.) with three operating subsidiaries, Live Well Medical Group (comprised of the primary care clinic locations nationally), The Good Clinic Properties, Inc. (which holds leases on all physical clinic locations), and Live Well Drugstore, Inc. (comprised of our current and future compounding pharmacy operations).
• We expect to be able to commence operations for the primary care and wellness clinics as part of our new strategy starting March 1, 2026.
• Our strategic commitment is to provide a more effective medical home by redefining primary care, through personalization of care and a broad spectrum of healthcare services that focus on improving the quality of life for our clients at every stage of their lives.
• The lower labor costs of employing Nurse Practitioners provide an approximate 25% margin improvement over the traditional primary care offices staffed with medical doctors.
• We believe our strategy of combining a full suite of primary care services and the specialized services of our competition in an operational environment focused on providing high quality care, excellent customer experience, personalized care plans and personalized medications has the potential to deliver our desired financial performance.
• It is our plan that the cost of our back-office operations will not increase in direct relation to the growth of our network of primary care clinics, which will allow us to sustain profit margins across our business operations with a cost effective and scalable back office.

Industry Context

StockSavvy.ai notes that First Choice Healthcare Solutions' strategic pivot aligns with broader healthcare trends emphasizing primary care, wellness, and personalized medicine, as highlighted by CMS reports on increasing healthcare expenditures and the need to strengthen primary care. The company's model of utilizing Nurse Practitioners for cost efficiency and integrated services (primary care, compounding pharmacy, quality-of-life services) positions it against a fragmented but competitive market including virtual providers (Hims, Ro), brick-and-mortar clinics (Oak Street Medical, One Medical), and specialized practices. The focus on self-pay quality-of-life services taps into a growing consumer demand for anti-aging, weight management, and hormone replacement therapies, which are high-growth segments. However, the success hinges on effective integration of acquisitions and navigating stringent regulatory environments for both clinics and compounding pharmacies.

Comparison to Industry Standards

• The company's strategy to use Nurse Practitioners (NPs) for primary care is supported by studies indicating NPs deliver care equal to, and in some measures better than, physicians, while offering an approximate 25% margin improvement due to lower labor costs compared to traditional primary care offices staffed with medical doctors.
• The U.S. primary care market is valued at $271.0 billion in 2023 and is expected to grow at a CAGR of 3.36% from 2024 to 2030, according to Grand View Research, indicating a significant market opportunity for the company's new strategy.
• The pharmaceutical weight loss market, a segment the company targets, was valued at $6 billion and could grow to $100 billion by 2030 (Goldman Sachs Research, October 2023), suggesting substantial growth potential.
• The Hormone Replacement Therapy (HRT) market, another target segment, was valued at $6.9 billion in 2022 and is expected to grow to $13.4 billion by 2032 (Global Market Insights, November 2023).
• The U.S. peptides market, relevant to personalized medicine, was valued at $17.8 billion in 2022 and is expected to grow at a CAGR of 7.0% from 2023 to 2030 (Global Market Insights, November 2023).
• The U.S. regenerative medicine market was estimated at $16.8 billion in 2023 and is projected to grow at a CAGR of 16.72% from 2024 to 2030 (Grand View Research), indicating high demand for advanced treatment options.
• The biohacking market, which the company aims to enter, was estimated at $23.9 billion in 2023 and is projected to grow at a CAGR of 19.48% to $67.9 billion by 2032 (Market Research Future), reflecting increasing interest in health optimization.

Management Changes

Corporate Governance

Legal Proceedings

• The company's former CEO, Christian C. Romandetti, Sr., pled guilty to conspiracy to commit securities fraud, which negatively impacted the company's reputation and business.
• The company filed for Chapter 11 bankruptcy on June 15, 2020, and emerged on April 27, 2022, with a reorganization plan that settled litigation and converted claims into unsecured creditors.
• A $7,500,000 put option held by Steward Health Care System, LLC was eliminated as part of the bankruptcy settlement.
• An open accounts payable liability of approximately $1,200,000 remains from a lease settlement order in October 2021, with the company working to reach a settlement with the landlord.
• A $19,473 judgment in favor of an equipment lessor was granted on January 25, 2024, which was subsequently negotiated down to a $9,000 settlement in March 2024.
• The company is named as a defendant in several employment-related matters, primarily due to unpaid wages following staff reductions and terminations, with most cases settled.

Related Party Transactions

• The company has notes payable to its Chief Executive Officer (Lance Friedman) totaling $2,142,105 as of September 30, 2025, and $1,626,983 as of December 31, 2024, related to deferred compensation, payments to third-party service providers, and other normal course of business items.
• Notes payable to the company's prior Chief Financial Officer amounted to $151,858 as of September 30, 2025, and December 31, 2024, also related to deferred compensation and business items.
• Pointe Medical Live Well group leases space under an operating lease agreement dated October 1, 2019, with Live Well Realty, LLC, which is a related party.
• The settlement of FCHS's lease obligations in Melbourne, Florida, involved Omni Healthcare, Inc., which was a long-standing business collaborator, landlord, and an investor in FCHS. The terms of the Series C conversion for this settlement remain unchanged per a verbal agreement.

Stakeholder Impact

• **Shareholders:** Existing common shareholders will experience immediate and substantial dilution due to the public offering of Series D Convertible Preferred Stock and warrants, and the 1-for-2,000 reverse stock split. The anti-dilution provisions of the Series D Preferred Stock could lead to further dilution. Selling stockholders from the private placement will have their shares issued without being subject to the reverse split, potentially giving them a relative advantage.
• **Employees:** The strategic pivot involves terminating all legacy orthopedic and physical therapy services, which will impact employees in those segments. The new strategy focuses on hiring Nurse Practitioners and medical assistants for primary care clinics, creating new employment opportunities. The company's ability to attract and retain qualified medical professionals is critical for its growth.
• **Customers/Patients:** The company aims to provide patient-centric personalized care through a national chain of primary care and wellness clinics, offering a broad spectrum of services including traditional primary care and self-pay quality-of-life services. The integrated model with an internal compounding pharmacy is designed to enhance patient experience and outcomes. However, reliance on the self-pay model for some services could limit patient utilization.
• **Creditors:** The public offering and associated capital raise are intended to settle certain notes payable and other liabilities, including lease obligations, by issuing Series C Preferred Stock, which could improve the company's balance sheet and reduce its overall indebtedness. The forgiveness of PPP loans also benefits the company's financial health.
• **Regulatory Bodies:** The company operates in a highly regulated healthcare and pharmacy industry, requiring strict compliance with federal and state laws (e.g., HIPAA, anti-kickback, Stark Law, compounding pharmacy regulations). Expansion into multiple states increases regulatory complexity and compliance risks, which could lead to penalties or operational restrictions if not managed effectively.

Next Steps

• Complete the public offering of Series D Convertible Preferred Stock and warrants.
• Uplist common stock to the NYSE under the symbol FCHS (or new name's symbol).
• Complete the 1-for-2,000 reverse stock split of common stock.
• Complete the 100% stock purchase acquisition of Pointe Medical Services, Inc., Pointe Med Pharmacy, Inc., Livewell MD, LLC, and Livewell Drugstore, LLC.
• Complete the asset purchase agreement to acquire physical and intangible assets of The Good Clinic, Inc.
• Commence operations for the primary care and wellness clinics as part of the new strategy, expected by March 1, 2026.
• Identify and appoint new board members to fill the full Board of Directors upon completion of the offering.
• Re-establish the Audit, Nominating and Governance, and Compensation Committees in the third quarter of 2025.
• Increase the number of state licensures for LiveWell Drugstore to include each state where primary care clinics operate.
• Pursue FDA approval for LiveWell Drugstore to become an FDA-registered 503B pharmacy.
• Expand compounding pharmacy operations to other states as the volume of business increases.
• Actively seek additional qualified and FDA-approved suppliers for pharmaceutical components.
• Open a total of thirty new clinics in the next four years, focusing initially on northeast and southwest Florida and Minnesota, and evaluating Denver and Phoenix markets.

Key Dates

Recommendation

First Choice Healthcare Solutions is undergoing a significant strategic transformation, pivoting from a struggling legacy orthopedic business to a potentially high-growth primary care and wellness model, supported by recent acquisitions and a planned public offering. While the new strategy targets attractive market segments and leverages a cost-effective Nurse Practitioner model, the company's substantial historical losses, accumulated deficit, and dependence on the success of this capital raise and integration efforts introduce considerable risk. The immediate dilution for existing shareholders from the offering and reverse stock split is a concern. A 'hold' recommendation is appropriate for seasoned investors, acknowledging the high-risk, high-reward nature of this pivot. Investors should monitor the successful execution of the acquisitions, the capital raise, NYSE listing, and the operational ramp-up of the new clinics before considering a 'buy' or 'sell' position. The company's ability to achieve profitability and manage regulatory complexities in its new ventures will be key determinants of future value.

Keywords

Healthcare Solutions, Primary Care, Wellness Clinics, Compounding Pharmacy, SEC Filing, Public Offering, Series D Preferred Stock, Warrants, Nurse Practitioners, Anti-aging, Weight Management, Hormone Replacement Therapy, Medical Equipment, Strategic Pivot, NYSE Listing, Dilution, Accredited Investor, Private Placement, Financial Reporting, Risk Factors